merck glp 1 agonist GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art Merck & Co. signs license
Description
Liraglutide Drugs BNF
The maximum approved dose of liraglutide for the treatment of obesity is 3 mg/day, whereas the maximum dose for the treatment of T2DM is 1.8 mg/day
doi:10.1111/dom.13326 180
An important consideration is that, if people prefer a device, they may be more willing to use the medication, potentially resulting in improved health outcomes
Some DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin) have been associated with severe joint pain [112]
